Literature DB >> 36255614

Analyzing Lymphoma Development and Progression Using HDACi in Mouse Models.

Eva-Maria Piskor1, René Winkler1,2, Christian Kosan3.   

Abstract

Besides the physiological role of histone deacetalylases in maintaining normal cellular integrity, the acetylation landscape is changed in cancer cells, which has been implicated as a potential target in cancer therapy. The overexpression of certain HDACs correlates with specific cancer types. Therefore, the development of specific HDAC inhibitors may extend the therapeutic strategy for cancer therapy. Here, we describe how to investigate the therapeutic potential of specific HDACi by treatment in a mouse model for B-cell lymphoma, exemplified by the HDAC6 inhibitor Marbostat-100.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  B-cell lymphoma; Flow cytometry; HDACi; Lymphomagenesis; Mouse model; Tumor progression

Mesh：

Substances：

Year:  2023        PMID： 36255614     DOI： 10.1007/978-1-0716-2788-4_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  25 in total

Review 1.  Anticancer activities of histone deacetylase inhibitors.

Authors:  Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.

Authors:  Sabnam Parbin; Swayamsiddha Kar; Arunima Shilpi; Dipta Sengupta; Moonmoon Deb; Sandip Kumar Rath; Samir Kumar Patra
Journal:  J Histochem Cytochem       Date:  2013-09-18       Impact factor: 2.479

3.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

4.  Increased expression of histone deacetylase 2 is found in human gastric cancer.

Authors:  Jaehwi Song; Ji Heon Noh; Jong Heun Lee; Jung Woo Eun; Young Min Ahn; Su Young Kim; Sug Hyung Lee; Won Sang Park; Nam Jin Yoo; Jung Young Lee; Suk Woo Nam
Journal:  APMIS       Date:  2005-04       Impact factor: 3.205

Review 5.  Interstrand Crosslink Repair as a Target for HDAC Inhibition.

Authors:  Teodora Nikolova; Nicole Kiweler; Oliver H Krämer
Journal:  Trends Pharmacol Sci       Date:  2017-07-04       Impact factor: 14.819

Review 6.  Oncogenes and tumor suppressor genes.

Authors:  Eva Y H P Lee; William J Muller
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-08-18       Impact factor: 10.005

Review 7.  Epigenetics and cancer.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

8.  Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Authors:  Kalipso Halkidou; Luke Gaughan; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

9.  O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

Authors:  P Freund; M A Kerenyi; M Hager; T Wagner; B Wingelhofer; H T T Pham; M Elabd; X Han; P Valent; F Gouilleux; V Sexl; O H Krämer; B Groner; R Moriggl
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

Review 10.  From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).

Authors:  Volker Schirrmacher
Journal:  Int J Oncol       Date:  2018-12-10       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.